TACE联合仑伐替尼及卡瑞利珠单抗治疗对肝细胞癌患者预后的影响  

Effect of TACE Combined with Lenvatinib and Camrelizumab on the Prognosis of Patients with Hepatocellular Carcinoma

作　　者：王彩霞 WANG Caixia(Department of Oncology,Taizhou Second People’s Hospital,Taizhou 225300,China)

机构地区：[1]泰州市第二人民医院肿瘤科,江苏泰州225300

出　　处：《反射疗法与康复医学》2025年第5期148-152,共5页Reflexology And Rehabilitation Medicine

摘　　要：目的 探讨经导管动脉化疗栓塞术(TACE)联合仑伐替尼及卡瑞利珠单抗治疗对肝细胞癌(HCC)患者预后的影响。方法 选择2020年1月—2023年1月泰州市第二人民医院收治的80例HCC患者为研究对象,按随机数字表法将其分为对照组和观察组,各40例。对照组采取TACE联合仑伐替尼治疗,观察组采取TACE联合仑伐替尼及卡瑞利珠单抗治疗。比较两组的临床疗效、肿瘤标志物、总生存情况及不良反应发生情况。结果 观察组疾病控制率为82.50%,高于对照组的62.50%,差异有统计学意义(P<0.05)。治疗3个疗程后,观察组血清癌胚抗原、糖类抗原125、糖类抗原19-9、甲胎蛋白水平均低于对照组,组间差异有统计学意义(P<0.05)。观察组生存率高于对照组,生存时间长于对照组,组间差异有统计学意义(P<0.05)。观察组不良反应发生率为2.50%,低于对照组的17.50%,差异有统计学意义(P<0.05)。结论 TACE联合仑伐替尼及卡瑞利珠单抗治疗HCC患者可有效控制疾病进展,降低肿瘤标志物水平,提高生存率,降低不良反应发生率,值得在临床中推广应用。Objective To investigate the effect of transcatheter arterial chemoembolization(TACE)combined with lenvatinib and camrelizumab on the prognosis of patients with hepatocellular carcinoma(HCC).Methods A total of 80 patients with HCC who were admitted to Taizhou Second People’s Hospital from January 2020 to January 2023 were selected as the research objects,according to the random number table method,they were divided into a control group and an observation group,with 40 cases in each group.The control group was treated with TACE combined with lenvatinib,and the observation group was treated with TACE combined with lenvatinib and camrelizumab.The clinical efficacy,tumor markers,overall survival and occurrence of adverse reactions were compared between the two groups.Results The disease control rate of the observation group was 82.50%,which was higher than 62.50%of the control group,and the difference was statistically significant(P<0.05).After 3 courses of treatment,the levels of serum carcinoembryonic antigen,carbohydrate antigen 125,carbohydrate antigen 19-9 and alpha-fetoprotein in the observation group were lower than those in the control group,and the differences between the two groups were statistically significant(P<0.05).The survival rate of the observation group was higher than that of the control group,and the survival time was longer than that of the control group,the difference between the two groups were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 2.50%,which was lower than 17.50%in the control group,and the difference was statistically significant(P<0.05).Conclusion TACE combined with lenvatinib and camrelizumab in the treatment of patients with HCC can effectively control the progression of the disease,reduce the level of tumor markers,improve the survival rate,and reduce the incidence of adverse reactions,which is worthy of clinical application.

关 键 词：肝细胞癌 经导管动脉化疗栓塞术 仑伐替尼 卡瑞利珠单抗 预后 

分 类 号：R735.7[医药卫生—肿瘤]